Clinical trials: Kidney Cancers
Lymphoma, Sarcoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Background: Vorinostat and bortezomib are anti-tumor drugs that have been approved by the Food and Drug Administration to treat different kinds of myeloma and lymphoma in adults.
- Conditions
- Lymphoma, Sarcoma, WilmsTumor, Neuroblastoma
- Trial name
- NCT01132911
- Testing
- Vorinostat (SAHA), Velcade (PS-341, Bortezomib)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Chemotherapeutic Toxicity
Role of Renal Biopsy in the Suspicion of Nephrotoxicity of Immunotherapy (Checkpoint Inhibitors) in Solid Cancer
Checkpoint inhibitors represent a new class of widely used immunotherapy, however with immune-mediated adverse effects, with renal damage estimated at 1.4% and 4.9% depending on the series.
- Trial name
- NEPHROTOX (NCT06357871)
- Testing
- No intervention
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Central Hospital, Nancy, France
Advanced Malignancy, Advanced Solid Tumors
A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors
This is a Phase 1 dose escalation to assess the safety, tolerability and maximum tolerated dose of subcutaneous administered SDX-7320 in patients with advanced refractory or late-stage solid tumors.
- Conditions
- Advanced Malignancy, Advanced Solid Tumors, Neoplasm, Metastasis
- Trial name
- SDX-0101 (NCT02743637)
- Testing
- SDX-7320
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- SynDevRx, Inc.
Actinic Keratosis
Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients
This is a single arm, open-label interventional study of ingenol mebutate 0.015% in solid organ transplant recipients. The investigators plan to treat 20 subjects, 10 kidney transplant recipients and 10 lung transplant…
- Trial name
- NCT02866695
- Testing
- ingenol mebutate gel 0.015%
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
Kidney Cancer
Carfilzomib in Refractory Renal Cell Carcinoma (RCC)
The goal of this clinical research study is learn if carfilzomib can help control kidney cancer. The safety of this drug will also be studied. Carfilzomib is designed to block cancer cells from repairing themselves.
- Trial name
- NCT01775930
- Testing
- Carfilzomib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Renal Cell
Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer
The purpose of this study is to learn if PET scanning can predict the degree of tumor shrinkage with the study drug RAD001 in subjects who have advanced renal cancer.
- Trial name
- NCT00529802
- Testing
- RAD001
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Chicago
Bladder Cancer, Cervical Cancer
Bupropion in Helping Adults Stop Smoking
RATIONALE: Bupropion may help people stop smoking by decreasing the symptoms of nicotine withdrawal. Giving bupropion over a longer period of time may be effective in helping people stop smoking.
- Conditions
- Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT00534001
- Testing
- bupropion hydrochloride
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- Roswell Park Cancer Institute
Carcinoma, Renal Cell
Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma
This was a randomized, open-label, parallel group Phase III non inferiority study to evaluate the efficacy and safety of pazopanib compared with sunitinib in subjects with advanced renal cell carcinoma (RCC) who had not received…
- Trial name
- COMPARZ (NCT00720941)
- Testing
- Pazopanib, Sunitinib
- Where
- 227 sites in United States, Australia and 12 more
- Volunteers
- 1,110 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma
Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment
Myeloma patients with renal impairment need a rapid and effective reduction of tumor burden to enable renal recovery, which is correlated with prognosis of the patients.
- Trial name
- GMMG-DANTE (NCT02977494)
- Testing
- Daratumumab, Bortezomib, Dexamethasone
- Where
- 10 sites in Germany, Greece
- Volunteers
- 22 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Locally Advanced or Metastatic Solid Tumours
A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer
This open labelled first in human dose phase 1/2a study is designed to evaluate safety, feasibility and efficacy of multiple dosing with individualised VB10.NEO and bempegaldesleukin (NKTR-214) immunotherapy in patients with…
- Trial name
- DIRECT-01 (NCT03548467)
- Testing
- VB10.NEO, Bempegaldesleukin
- Where
- 6 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Nykode Therapeutics ASA
Advanced Malignancies, Metastatic Cancer
A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors
This was an open-label, non-randomized Phase 1/2 safety study of INCAGN01876 in participants with advanced or metastatic solid tumors that was conducted in 2 parts.
- Trial name
- NCT02697591
- Testing
- INCAGN01876
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- Incyte Biosciences International Sàrl
Metastatic Renal Cancer
Lu-177 PSMA Treatment in Cell Renal Carcinoma
Summary Renal Cell Carcinoma (RCC) consists of 2% of all malignencies. RCCs are generally divided to histopathological subtypes as clear cell and non-clear cell variants. Clear cell variant responsible for the 75-80% of all RCCs.
- Trial name
- NCT06959433
- Testing
- Lu-177 PSMA-617
- Volunteers
- 20 people
- Sponsor
- Ankara University
Basal Ganglia Germinoma, Diabetes Insipidus
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
This phase II trial studies how well lower dose radiotherapy after chemotherapy (Carboplatin \& Etoposide) works in treating children with central nervous system (CNS) germinomas.
- Conditions
- Basal Ganglia Germinoma, Diabetes Insipidus, Germinoma, Pineal Region Germinoma
- Trial name
- NCT06368817
- Testing
- 3-Dimensional Conformal Proton Radiation Therapy, 3-Dimensional Conformal Radiation Therapy, Biospecimen Collection
- Where
- 115 sites in United States, Australia and 1 more
- Volunteers
- 240 people
- Sponsor
- Children's Oncology Group
Metastatic Clear Cell Renal Cell Carcinoma
Imaging Study in Metastatic Clear Cell RCC.
This imaging study aims to assess the feasibility, biodistribution, and dosimetry of the imaging agent in Subjects with Metastatic Clear Cell Renal Cell Cancer (RCC).
- Trial name
- NCT07671417
- Testing
- RYZ512
- Where
- 6 sites in Australia, New Zealand and 1 more
- Volunteers
- 10 people
- Sponsor
- RayzeBio, Inc.
Cervical Cancer, HEENT Cancer
Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors
The purpose of this study is to evaluate low oxygen areas called hypoxia within the tumor. These low oxygen areas are thought to be the reason why tumors are more resistant to radiation treatment.
- Conditions
- Cervical Cancer, HEENT Cancer, Renal Cancer, Uterine Cancer
- Trial name
- NCT00588276
- Testing
- 124I-Iodo-Azomycin Galacto-Pyranoside
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Renal Cell Carcinoma
RF Ablation of Treatment of Metastatic Lesions in Patients Undergoing Antiangiogenic Therapy for Stage IV Renal Cell Carcinoma
The purpose of this study is to look at the effects of a procedure called radiofrequency ablation on kidney tumors from patients who are undergoing antiangiogenic treatment.
- Trial name
- NCT00601120
- Testing
- Radiofrequency Ablation
- Where
- United States
- Sponsor
- Beth Israel Deaconess Medical Center
Metastatic Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy
This phase II trial tests how well zanzalintinib and MO-03 works for the treatment of renal cell cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and that is growing…
- Trial name
- NCT07578025
- Testing
- Biospecimen Collection, Bone Scan, C. butyricum CBM 588 Probiotic Strain Capsule Formulation MO-03
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- City of Hope Medical Center
Advanced Renal Cell Carcinoma, Advanced Melanoma
Sitagliptin With Pembro in RCC and Melanoma
This study is testing whether adding the drug sitagliptin to the standard immunotherapy pembrolizumab is safe and may help people with advanced melanoma or advanced renal cell carcinoma (kidney cancer) whose cancer has stopped…
- Trial name
- NCT07634380
- Testing
- Sitagliptin, Pembrolizumab
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Fernando Maciel Barbosa
Renal Cell Cancer, Advanced Renal Cell Cancer
Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides
Clinical Phase I/II study to investigate the feasibility and tolerability of synthetic adjuvant peptide immunisation in combination with immune adjuvants (granulocyte macrophage colony stimulating factor; Montanide ISA-51) in…
- Trial name
- UroRCC (NCT02429440)
- Testing
- peptide vaccine, Granulocyte Macrophage Colony Stimulating Factor, Montanide ISA-51
- Volunteers
- 40 people
- Sponsor
- University Hospital Tuebingen
Unspecified Complications of Kidney Transplant, Disorder Related to Renal Transplantation
Evaluation of Sun Protection Education for Kidney Transplant Recipients
This study is being done to evaluate the effectiveness of a Sun Protection Strategies workbook for kidney transplant recipients.
- Trial name
- NCT01844713
- Testing
- Workbook
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- Northwestern University